ecancermedicalscience

Short Communication

Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

10 Dec 2008
P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, G Sanz, AF List, SD Gore, JF Seymour, J Backstrom, L Zimmerman, D McKenzie, CL Beach, LB Silverman

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (¡Ý20¨C30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

Related Articles

Rachael O Oduyemi, Chizoma Millicent Ndikom, Gloria Oluwakorede Alao, Iyanuoluwa O Ojo, Faith Ayomide Ajayi, Damilola Ajibade, Abdullahi Suleiman, Hameedah Ayomide Gbadamosi, Oluwadamilare Akingbade
Kaio Mota-Ribeiro, Maria P Curado, Betine P M Iser, Mohsen Naghavi, Deborah C Malta, Max M Oliveira
Agnes Chipo Tererai, Margaret Borok, Zvavahera Mike Chirenje, Liz Gwyther, Lindsay Farrant, Ntokozo Ndlovu, Simbarashe Rusakaniko
Elhadji Daouda Niang, Seynabou Fall, Sokhna Aissatou Toure, Marieme Lolita Camara, Modou Moustapha Ciss, Adjaratou Tiane Niang, Khadim Sarr, Amy Thiam, Fatou Samba Diago Ndiaye
Prajwal Dhakal, Christopher S Wichman, Shailesh Simkhada, Bunny J Pozehl, Radowan Elnair, Amulya Yellala, Kalika Mahato, Vijaya Raj Bhatt
Prasoon Mishra, Rahat Hadi, Ajeet Kumar Gandhi, Madhup Rastogi, Rohini Khurana, Ashish Singhal, Surendra Prasad Mishra, Anoop Srivastava, Avinav Bharati, Ashish Chandra Agarwal, Avinash Poojari, Vachaspati Kumar Mishra, Raunaq Puri, Akanksha Manral, Vikas Gupta, Bhoopendra Pratap Vishwaranjan, Saumyta Mishra